Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
31
12
2020
revised:
11
03
2021
accepted:
29
04
2021
pubmed:
6
5
2021
medline:
2
4
2022
entrez:
5
5
2021
Statut:
ppublish
Résumé
Poly (ADP ribose)-polymerase (PARP) inhibitors are approved for use in breast, ovarian, prostate, and pancreatic cancers, which are the solid tumor types that most frequently have alterations in key homologous recombination (HR) genes, such as Specific DNA aberration profiles (mutational signatures) are induced by HRD, and the presence of these "genomic scars" can be used to assess the presence or absence of HRD in a given tumor biopsy even in the absence of an observed alteration of an HR gene. Using whole-exome and whole-genome data, we measured various HRD-associated mutational signatures in bladder cancer. We found that a subset of bladder tumors have evidence of HRD. In addition to a small number of tumors with biallelic A subset of bladder tumors have genomic features suggestive of HRD and therefore may be more likely to benefit from therapies such as platinum agents and PARP inhibitors that target tumor HRD.
Identifiants
pubmed: 33947694
pii: 1078-0432.CCR-20-5037
doi: 10.1158/1078-0432.CCR-20-5037
pmc: PMC8896908
mid: NIHMS1720423
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
3734-3743Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : K08 CA219504
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Eur Urol. 2018 Mar;73(3):462-468
pubmed: 29273410
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Bioinformatics. 2016 Apr 15;32(8):1244-6
pubmed: 26656004
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
J Clin Oncol. 2018 Jul 1;36(19):1949-1956
pubmed: 29742009
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Cancer Discov. 2015 Nov;5(11):1210-23
pubmed: 26482930
Clin Epigenetics. 2018 Feb 6;10:15
pubmed: 29445424
Cancer Res. 2009 Aug 15;69(16):6381-6
pubmed: 19654294
Genome Biol. 2016 Feb 22;17:31
pubmed: 26899170
Genome Biol. 2019 Nov 14;20(1):240
pubmed: 31727117
Ann Oncol. 2015 Jan;26(1):64-70
pubmed: 25319062
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Mol Cell. 2018 Nov 1;72(3):568-582.e6
pubmed: 30344097
NPJ Breast Cancer. 2019 Aug 8;5:23
pubmed: 31428676
Clin Genitourin Cancer. 2012 Mar;10(1):1-5
pubmed: 22340630
NPJ Breast Cancer. 2018 Jul 2;4:16
pubmed: 29978035
Lancet Oncol. 2003 Aug;4(8):489-97
pubmed: 12901963
Cancer Res. 2012 Nov 1;72(21):5454-62
pubmed: 22933060
JAMA. 2012 Jan 25;307(4):382-90
pubmed: 22274685
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
Clin Cancer Res. 2021 Apr 1;27(7):2011-2022
pubmed: 33208343
Eur Urol Oncol. 2020 Aug;3(4):544-547
pubmed: 32165095
Br J Cancer. 2012 Nov 6;107(10):1776-82
pubmed: 23047548
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Clin Cancer Res. 2017 Dec 15;23(24):7521-7530
pubmed: 29246904
J Pathol. 2017 Jun;242(2):165-177
pubmed: 28299801
Nature. 2009 May 21;459(7245):460-3
pubmed: 19357644
Am J Hum Genet. 2017 Feb 2;100(2):267-280
pubmed: 28132688
Clin Cancer Res. 2017 Jul 15;23(14):3610-3618
pubmed: 28137924
Oncotarget. 2016 Feb 16;7(7):7701-14
pubmed: 26713604
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
J Clin Oncol. 2010 Mar 1;28(7):1145-53
pubmed: 20100965
Cancer Discov. 2012 Apr;2(4):366-375
pubmed: 22576213
Cancer Discov. 2014 Oct;4(10):1140-53
pubmed: 25096233
J Clin Invest. 2020 Aug 3;130(8):4069-4080
pubmed: 32379725
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
JAMA Oncol. 2016 Aug 1;2(8):1094-6
pubmed: 27310333
Nat Genet. 2017 Oct;49(10):1476-1486
pubmed: 28825726
Nat Commun. 2020 Sep 25;11(1):4858
pubmed: 32978382
Nat Genet. 2017 Dec;49(12):1779-1784
pubmed: 29083409
Genome Res. 2018 May;28(5):654-665
pubmed: 29632087
Cell. 2016 Jul 28;166(3):740-754
pubmed: 27397505
Clin Cancer Res. 2020 Jun 1;26(11):2673-2680
pubmed: 32071115
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110